<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516200</url>
  </required_header>
  <id_info>
    <org_study_id>P.T.REC/012/002000</org_study_id>
    <nct_id>NCT04516200</nct_id>
  </id_info>
  <brief_title>Effect of Transcranial Direct Current Stimulation on Sensory Integration</brief_title>
  <official_title>Effect of Transcranial Direct Current Stimulation on Sensory Integration and Risk of Falling in Diabetic Polyneuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MTI University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MTI University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of Transcranial direct current stimulation on sensory integration and&#xD;
      risk of falling in diabetic polyneuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE:&#xD;
&#xD;
      To determine the effect of Transcranial direct current stimulation on sensory integration and&#xD;
      risk of falling in diabetic polyneuropathy.&#xD;
&#xD;
      BACKGROUND:&#xD;
&#xD;
      Diabetic polyneuropathy is the most prevalent chronic complication affecting 30% - 50% of&#xD;
      diabetic patients. Diabetic polyneuropathy usually affect the peripheral, autonomic, and&#xD;
      central nervous systems with several clinical symptoms .About 80% of the cases of DN manifest&#xD;
      as distal symmetrical sensorimotor polyneuropathy which is responsible for cases of chronic&#xD;
      pain; impaired sleep quality; increase of the falling risk associated with weakness and&#xD;
      increase of the risk of extremities amputation. Transcranial direct current stimulation is&#xD;
      neurophysiologic intervention that alters cortical excitability to enhance lower extremity&#xD;
      somato-sensation and thus improve functional outcomes.&#xD;
&#xD;
      HYPOTHESES:&#xD;
&#xD;
      There will be no effect of Transcranial direct current stimulation on sensory integration and&#xD;
      risk of falling in diabetic polyneuropathy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group 1: transcranial direct current stimulation and traditional physical therapy program Group 2: the same traditional physical therapy program</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blind masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>sway index of sensory integration test</measure>
    <time_frame>two months</time_frame>
    <description>sway index of sensory integration test will be measured by biodex balance system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>risk of fall index</measure>
    <time_frame>two months</time_frame>
    <description>risk of fall index will be measured by biodex balance system</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Polyneuropathy</condition>
  <arm_group>
    <arm_group_label>Transcranial direct current stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcranial direct current stimulation will be applied to study group only . Anodal transcranial stimulation will be applied on left somatosensory cortex while the cathodal one will be applied on right supra-orbital area with frequency of 2m.A for 20 minutes.Stimulation will be applied three times per week for two months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>traditional physical therapy program</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>traditional physical therapy program will be applied to both the control group and study group. It will be consist of sensory re-education training and balance training.Exercises will be applied three times per week for two months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation and traditional physical therapy program</intervention_name>
    <description>Transcranial stimulation will be applied only for the study group.</description>
    <arm_group_label>Transcranial direct current stimulation</arm_group_label>
    <other_name>Gymna- uniphy(phy-action 787)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>designed physical therapy program</intervention_name>
    <description>sensory training and balance training</description>
    <arm_group_label>Transcranial direct current stimulation</arm_group_label>
    <arm_group_label>traditional physical therapy program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1 - Patient will be diagnosed as having Diabetic Polyneuropathy (DPN) and all patients have&#xD;
        type II diabetes.&#xD;
&#xD;
        2-The age of the patients ranged from 35 to 55 years.&#xD;
&#xD;
        3-Clinically all patients suffered from glove stock hyposthesia, numbness and burning&#xD;
        sensation and mild distal moror weakness&#xD;
&#xD;
        4-Patients have sensorymotor peripheral neuropathy according to neurophysiological study to&#xD;
        detect sensory and motor conduction velocity to confirm diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of diabetic ulcer and amputation .&#xD;
&#xD;
          2. Osteoporosis.&#xD;
&#xD;
          3. Fractures of lower limbs.&#xD;
&#xD;
          4. Gross musculoskeletal problems eg:burn.&#xD;
&#xD;
          5. Significant Scar tissue or calluses on the feet.&#xD;
&#xD;
          6. Peripheral vascular diseases (PVD) or Microcirculation problems.&#xD;
&#xD;
          7. Balance disturbance rather than diabetic peripheral neuropathy as ear problems,&#xD;
             labrynthinitis, stroke or cerebellar problems.&#xD;
&#xD;
          8. Visual disturbance.&#xD;
&#xD;
          9. Autonomic neuropathy.&#xD;
&#xD;
         10. Advanced Osteoarthritis of lower limbs.&#xD;
&#xD;
         11. Nerve root compression (Radicuolopathy) affecting lower limbs.&#xD;
&#xD;
         12. Patients with implanted devices for pain control such as deep brain&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MTI University</investigator_affiliation>
    <investigator_full_name>Sara Salah El-Din Abdel Megeed</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT04516200/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

